Century Therapeutics (IPSC) AI Stock Analysis

• Market Cap: $420.55M
• Dividend Yield: N/A
• Average Volume (3M): 1.08M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.95
• Revenue Growth: 4121.12%
• EPS Growth: 83.30%
• Country: US
• Employees: 140
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.25
• Shares Outstanding: 179,647,830
• 10 Day Avg. Volume: 1,339,606
• 30 Day Avg. Volume: 1,077,469
• PEG Ratio: 0.10
• Price to Book (P/B): 0.54
• Price to Sales (P/S): 0.79
• P/FCF Ratio: -0.83
• Enterprise Value/Market Cap: 0.43
• Enterprise Value/Revenue: 1.68
• Enterprise Value/Gross Profit: 1.84
• Enterprise Value/Ebitda: -94.34
• 1Y Price Target: $5.30
• Price Target Upside: 126.50% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -0.58
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: $3.00 ▲(28.21% Upside)
• Action: Reiterated Date: 03/12/26
• Date: Action: Reiterated 03/12/26

The score is held back mainly by heavy ongoing cash burn and uneven revenue visibility, despite an improved loss profile and a manageable balance sheet. Offsetting this, the stock’s technical setup is strong and recent financing/pipeline progress provides near-term support, while valuation remains constrained by negative earnings and no dividend.

Positive Factors

Strengthened balance sheet via $135M financing

An oversubscribed $135M private placement materially improves Century's funding runway and reduces near-term financing pressure. This durable capital cushion supports IND-enabling work, parallel program advancement, and lowers the immediate risk of disruptive equity raises, enabling execution on multi-year clinical timelines.

Material clinical progress on CNTY-813

Clear preclinical efficacy, completion of a GMP master cell bank, and a targeted IND timeline meaningfully de-risk the lead program. Achieving IND and initial clinical readouts would be durable value drivers, validating the technical approach and making future partnerships, milestone payments, or commercialization more attainable.

Platform breadth: Allo‑Evasion tech and multiple programs

A proprietary Allo‑Evasion platform and multiple programs in IND‑enabling or early clinical stages diversify program risk and create potential platform-scale advantages. Parallel advancement across oncology, autoimmune and T1D increases optionality and improves the firm's strategic position versus single-product peers.

Negative Factors

Sustained negative operating cash flow

Large and persistent cash burn is a structural vulnerability: even with recent financing, ongoing negative operating and free cash flow imply continued reliance on external capital or milestone income. Over 2-6 months, sustained burn raises dilution risk and constrains strategic flexibility if clinical timelines slip or expected payments are delayed.

High revenue volatility and limited visibility

Revenue is uneven and largely collaboration-driven, producing sharp period-to-period swings. That structural volatility limits predictable operating cash inflows and complicates planning for R&D investment. Until recurring, diversified revenue sources emerge, funding and forecast visibility will remain constrained.

Ongoing unprofitability and negative returns on equity

Although equity capital supports operations today, negative ROE and continued net losses show the balance sheet is financing value destruction rather than compounding it. Long-term value creation requires successful clinical outcomes or durable commercial revenue; without them, equity dilution or impaired returns are likely.

Century Therapeutics Business Overview & Revenue Model

Company Description

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

How the Company Makes Money

Century Therapeutics does not primarily generate revenue from product sales because its therapeutic candidates are in clinical development and are not commercialized. The company’s revenue, when reported, has primarily come from collaboration and license arrangements, such as upfront payments, research funding, and other payments related to partnered development activities; milestone payments and royalties may be possible under such agreements but are not guaranteed and depend on achieving specified development, regulatory, or commercial events. The company also funds operations through financing activities (e.g., issuing equity or other capital-raising transactions), which support R&D but are not revenue from operations. Specific counterparties, deal terms, and the current contribution of any individual partnership to earnings: null.

Century Therapeutics Financial Statement Overview

Summary

Mixed fundamentals. The balance sheet is relatively supportive (debt-to-equity ~0.25 and positive equity), and losses have narrowed materially (TTM net loss ~$9.6M). However, cash flow is a major weakness (TTM operating cash flow about -$103.9M and negative free cash flow), and revenue has been volatile with a sharp TTM decline, raising funding and visibility risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue is sizable at ~$109.2M with very high gross profitability (~94% gross margin), reflecting strong economics on the revenue being recognized. However, the company remains unprofitable (TTM net loss of ~$9.6M) and operating profitability is still negative, though losses are dramatically smaller than prior annual periods (2024–2022 showed much larger losses). A key watch-out is the sharp TTM revenue decline (reported growth of -368%), highlighting volatility and limited consistency typical of development-stage biotech revenue.

Balance Sheet

Leverage looks manageable with TTM total debt of ~$40.2M against ~$158.9M of equity (debt-to-equity ~0.25), an improvement versus 2024 (~0.33) and broadly conservative for the sector. The equity base remains positive and meaningful relative to assets (~$223.7M total assets), supporting financial flexibility. The main weakness is continued negative returns for shareholders (TTM return on equity is negative), indicating the balance sheet is funding ongoing losses rather than compounding value.

Cash Flow

Cash generation is the primary pressure point: TTM operating cash flow is deeply negative (~-$103.9M) and free cash flow is also negative (~-$104.7M), implying a sustained cash burn profile. Free cash flow also deteriorated versus the prior period (TTM free cash flow growth reported at -708%), increasing financing risk if burn persists. While cash burn aligns with biotech R&D investment, the current run-rate suggests ongoing reliance on external capital unless profitability and/or cash inflows improve.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	109.16M	6.59M	2.23M	5.20M	0.00
Gross Profit	0.00	6.59M	2.23M	5.20M	-4.58M
EBITDA	-17.27M	-111.47M	-121.21M	-121.20M	-89.92M
Net Income	-9.58M	-126.57M	-136.67M	-130.93M	-95.82M
Balance Sheet
Total Assets	223.70M	353.22M	360.69M	486.54M	437.38M
Cash, Cash Equivalents and Short-Term Investments	117.11M	189.29M	172.74M	315.50M	222.88M
Total Debt	40.24M	53.83M	48.17M	49.41M	25.12M
Total Liabilities	64.77M	191.85M	175.94M	183.81M	41.14M
Stockholders Equity	158.94M	161.36M	184.75M	302.74M	396.24M
Cash Flow
Free Cash Flow	-103.88M	-110.29M	-102.08M	-16.55M	-133.97M
Operating Cash Flow	-103.88M	-110.14M	-88.35M	14.05M	-89.00M
Investing Cash Flow	107.50M	47.48M	61.13M	-13.13M	-298.34M
Financing Cash Flow	173.00K	74.56M	-9.72M	27.16M	417.77M

Century Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.34
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IPSC, the sentiment is Positive. The current price of 2.34 is above the 20-day moving average (MA) of 2.31, above the 50-day MA of 2.05, and above the 200-day MA of 0.94, indicating a bullish trend. The MACD of 0.19 indicates Positive momentum. The RSI at 52.24 is Neutral, neither overbought nor oversold. The STOCH value of 44.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IPSC.

Century Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IPSC	55 Neutral	$420.55M	―	-4.88%	―	4121.12%	83.30%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LTRN	50 Neutral	$26.73M	―	-125.98%	―	―	1.18%
BTAI	47 Neutral	$36.28M	-0.29	―	―	-66.96%	71.83%
ATNM	45 Neutral	$34.63M	-2.43	-151.67%	―	11.11%	20.65%
TPST	44 Neutral	$30.47M	-3.25	-405.03%	―	―	49.43%
CALC	41 Neutral	$13.07M	-3,346.34	-526.36%	―	―	-2.46%

Century Therapeutics Corporate Events

Century Therapeutics Reports 2025 Results and Pipeline Progress

On March 12, 2026, Century Therapeutics reported its full-year 2025 results, highlighting progress on CNTY-813, a beta islet replacement therapy for type 1 diabetes, and CNTY-308, a CD19-targeted CAR-iT cell candidate for B-cell-mediated diseases. CNTY-813 showed compelling preclinical data, including over six months of normoglycemia in animal models and completion of a GMP master cell bank, with the company targeting an IND filing in the fourth quarter of 2026 and initial clinical data in the second half of 2027.

CNTY-308 remained on track for first-in-human studies in 2026 after demonstrating functional comparability to primary CAR-T cells, while additional data from the CNTY-101 CARAMEL investigator-sponsored autoimmune study are expected during 2026. Financially, Century cut its 2025 net loss to $9.6 million from $126.6 million in 2024, driven by a jump in Bristol-Myers Squibb collaboration revenue and lower R&D and G&A expenses, and an oversubscribed $135 million private placement in January 2026 extended its cash runway into the first quarter of 2029.

The most recent analyst rating on (IPSC) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.

Century Therapeutics Regains Nasdaq Compliance, Halts Reverse Split

On January 22, 2026, Century Therapeutics, Inc. held a virtual special meeting of stockholders at which shareholders approved an amendment to the company’s certificate of incorporation authorizing a potential reverse stock split of its common shares at a ratio between 1-for-5 and 1-for-30, subject to the board’s discretion. On the same day, the company received notice from Nasdaq that it had regained compliance with the exchange’s minimum $1.00 bid price requirement and all other continued listing standards, leading Century Therapeutics to announce it does not intend to implement the reverse stock split, a decision that stabilizes its listing status and avoids the immediate dilutionary and structural impacts such a split might have had on existing shareholders.

The most recent analyst rating on (IPSC) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.

Century Therapeutics Highlights Progress in Immune-Evasive Cell Therapies

On January 12, 2026, Century Therapeutics updated an investor slide presentation detailing progress across its cell therapy pipeline and plans to unlock the value of its programs in Type 1 diabetes and autoimmune disease. The company highlighted that CNTY-813 and CNTY-308, both incorporating its Allo-Evasion 5.0 technology for enhanced immune evasion and persistence, are in IND-enabling studies with CNTY-813 targeted for an investigational filing in 2026 and early clinical data expected in 2027, while CNTY-308 is anticipated to enter the clinic in 2026. Century also reported that patient enrollment is ongoing in the Phase 1/2 CARAMEL investigator-sponsored trial of CNTY-101 in autoimmune disease, and said its cash runway extends beyond planned key clinical milestones, underscoring its capacity to advance multiple high-impact programs in parallel and strengthen its position as a leader in immune-evasive allogeneic cell therapies.

The most recent analyst rating on (IPSC) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.

Century Therapeutics Announces Oversubscribed $135 Million Financing

On January 7, 2026, Century Therapeutics entered into a securities purchase agreement with institutional investors for an oversubscribed private placement expected to close on January 9, 2026, raising approximately $135 million in gross proceeds through the sale of about 117.4 million shares of common stock (or pre-funded warrants) and accompanying warrants priced in line with Nasdaq “Minimum Price” requirements. The financing, led by new investor TCGX with participation from RA Capital, Commodore Capital, Deep Track Capital, RTW Investments, Venrock Healthcare Capital Partners, the T1D Fund and others, strengthens Century’s balance sheet to support development of its lead iPSC-derived beta islet cell therapy candidate CNTY-813 for Type 1 diabetes, including funding toward an investigational new drug filing planned for 2026 and initial clinical data expected in 2027, and could deliver an additional roughly $153 million if all warrants are exercised, while also committing the company to register the resale of the issued securities under a new registration rights agreement.

The most recent analyst rating on (IPSC) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.

Century Therapeutics announces resignation of board member

On December 18, 2025, Century Therapeutics, Inc. announced that board member Carlo Rizzuto, Ph.D., resigned from its board of directors, effective the same day. The company emphasized that Rizzuto’s departure did not arise from any disagreement over its operations, policies, or practices, and publicly expressed appreciation for his distinguished service and lasting contributions to the organization.

The most recent analyst rating on (IPSC) stock is a Hold with a $0.90 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.

Century Therapeutics Updates on Cell Therapy Advancements

On December 12, 2025, Century Therapeutics updated its slide presentation to reflect advancements in its cell therapy pipeline, which will be used in investor meetings. The company is progressing with its Allo-Evasion technology, with key programs like CNTY-101 in Phase 1/2 trials for autoimmune diseases and CNTY-813 in preclinical development for Type 1 Diabetes. The announcement highlights the company’s strategic focus on executing high-impact programs and extending its cash runway beyond key clinical milestones anticipated in late 2027.

The most recent analyst rating on (IPSC) stock is a Hold with a $0.56 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.